Catalyst Biosciences Inc

NASDAQ:CBIO  
4.00
-0.16 (-3.85%)
Products

Catalyst Biosciences Receives FDA Fast Track Designation For Subcutaneous Marzaa For The Treatment Of Episodic Bleeding In Hemophilia A Or B

Published: 12/02/2020 13:25 GMT
Catalyst Biosciences Inc (CBIO) - Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous Marzaa for the Treatment of Episodic Bleeding in Hemophilia a Or B With Inhibitors.
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous Marzaa for the Treatment of Episodic Bleeding in Hemophilia a Or B With Inhibitors.
Catalyst - Marzaa for Treatment of Episodic Bleeding in Subjects With Hemophilia a Or B With Inhibitors Will Enter Phase 3 Study Crimson 1 This Month.